Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

105.80 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 105.80
Bid (Size) 102.00 (1)
Ask (Size) 115.00 (1)
Prev. Close 105.80
Today's Range 105.80 - 105.80
52wk Range 49.24 - 112.12
Shares Outstanding 16,676,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Looking Into Ligand Pharmaceuticals's Recent Short Interest
Via Benzinga

Performance

YTD
+46.31%
+46.31%
1 Month
+7.82%
+7.82%
3 Month
+20.35%
+20.35%
6 Month
+38.70%
+38.70%
1 Year
+66.54%
+66.54%

More News

Read More
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
Via Investor's Business Daily
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts
Via Benzinga
What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
Via Benzinga
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
Via Investor's Business Daily
Ligand Reports Second Quarter 2024 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
5 Best Short-Term Stocks to Consider Investing In
Via MarketBeat
Ligand to Acquire APEIRON Biologics AG for $100 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Lifecore Biomedical Announces Cooperation Agreement with 22NW
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Participate in Upcoming Investor Conferences
From Ligand Pharmaceuticals Incorporated
Via Business Wire
3 Magnificent Growth Stocks to Buy Hand Over Fist
Via The Motley Fool
Topics Economy
Exposures Interest Rates
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
Via InvestorPlace
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Ligand Reports First Quarter 2024 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Don't Overlook These Top Medical Stocks As Q1 Earnings Approach
Via Talk Markets
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
7 Small-Cap Stocks for the Thinking Speculator
Via InvestorPlace
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.